REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · IEX Real-Time Price · USD
12.20
-0.38 (-3.02%)
Jul 22, 2024, 10:00 AM EDT - Market open
REGENXBIO Employees
REGENXBIO had 344 employees as of December 31, 2023. The number of employees decreased by 57 or -14.21% compared to the previous year.
Employees
344
Change (1Y)
-57
Growth (1Y)
-14.21%
Revenue / Employee
$252,110
Profits / Employee
-$756,244
Market Cap
622.35M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Ginkgo Bioworks Holdings | 1,218 |
ProKidney | 163 |
Entrada Therapeutics | 159 |
KalVista Pharmaceuticals | 150 |
Astria Therapeutics | 59 |
Celcuity | 55 |
ArriVent BioPharma | 40 |
Corbus Pharmaceuticals Holdings | 19 |
RGNX News
- 4 weeks ago - REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients - PRNewsWire
- 4 weeks ago - REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II - PRNewsWire
- 5 weeks ago - REGENXBIO Announces Leadership Transition - PRNewsWire
- 6 weeks ago - REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - PRNewsWire
- 2 months ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 2 months ago - REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 3 months ago - REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - PRNewsWire